{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:45:57Z","timestamp":1747172757537,"version":"3.40.5"},"reference-count":127,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"unspecified","delay-in-days":350,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Rev. Mol. Med."],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and significantly impacts the world economy and daily life. Symptoms of COVID-19 range from asymptomatic to fever, dyspnoea, acute respiratory distress and multiple organ failure. Critical cases often occur in the elderly and patients with pre-existing conditions. By binding to the angiotensin-converting enzyme 2 receptor, SARS-CoV-2 can enter and replicate in the host cell, exerting a cytotoxic effect and causing local and systemic inflammation. Currently, there is no specific treatment for COVID-19, and immunotherapy has consistently attracted attention because of its essential role in boosting host immunity to the virus and reducing overwhelming inflammation. In this review, we summarise the immunopathogenic features of COVID-19 and highlight recent advances in immunotherapy to illuminate ideas for the development of new potential therapies.<\/jats:p>","DOI":"10.1017\/erm.2021.30","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T09:15:47Z","timestamp":1639732547000},"source":"Crossref","is-referenced-by-count":4,"title":["The immunology and immunotherapy for COVID-19"],"prefix":"10.1017","volume":"23","author":[{"given":"Yixin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-1593","authenticated-orcid":false,"given":"Xiaotao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"S1462399421000302_ref32","first-page":"281","article-title":"Cause analysis and treatment strategies of \u2018recurrence\u2019 with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital","volume":"43","author":"Zhou","year":"2020","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"S1462399421000302_ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111957"},{"key":"S1462399421000302_ref118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-023770"},{"key":"S1462399421000302_ref97","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25907"},{"key":"S1462399421000302_ref13","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01537"},{"key":"S1462399421000302_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa387"},{"key":"S1462399421000302_ref20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"S1462399421000302_ref122","doi-asserted-by":"publisher","DOI":"10.1080\/09553000701317358"},{"key":"S1462399421000302_ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.025"},{"key":"S1462399421000302_ref53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248"},{"key":"S1462399421000302_ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0602-4"},{"key":"S1462399421000302_ref89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659"},{"key":"S1462399421000302_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025"},{"key":"S1462399421000302_ref126","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0551-y"},{"key":"S1462399421000302_ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839"},{"key":"S1462399421000302_ref105","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30132-8"},{"key":"S1462399421000302_ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.05.020"},{"key":"S1462399421000302_ref83","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0263"},{"key":"S1462399421000302_ref73","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00813-8"},{"key":"S1462399421000302_ref60","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8665"},{"key":"S1462399421000302_ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.06.005"},{"key":"S1462399421000302_ref52","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0198"},{"key":"S1462399421000302_ref117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031118"},{"key":"S1462399421000302_ref17","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171550"},{"key":"S1462399421000302_ref85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24339-7"},{"key":"S1462399421000302_ref48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa150"},{"key":"S1462399421000302_ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25678"},{"key":"S1462399421000302_ref112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01143-2"},{"key":"S1462399421000302_ref119","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14768"},{"key":"S1462399421000302_ref103","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"S1462399421000302_ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z"},{"key":"S1462399421000302_ref79","article-title":"Subcutaneous REGEN-COV antibody combination for COVID-19 prevention","author":"O'Brien","year":"2021","journal-title":"medRxiv"},{"key":"S1462399421000302_ref78","first-page":"ofab315","article-title":"Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019","volume":"7","author":"Blake","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"S1462399421000302_ref70","first-page":"1","article-title":"Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses","author":"Nezhad","year":"2020","journal-title":"Preprints"},{"key":"S1462399421000302_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.026"},{"key":"S1462399421000302_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102763"},{"key":"S1462399421000302_ref6","article-title":"Real-time estimation of the risk of death from novel coronavirus (COVID-19) infection: inference using exported cases","volume":"9","author":"Jung","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"S1462399421000302_ref67","article-title":"The abstruse side of type I interferon immunotherapy for COVID-19 cases with comorbidities","volume":"34","author":"Subbian","year":"2021","journal-title":"Journal of Respiration"},{"key":"S1462399421000302_ref109","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060667"},{"key":"S1462399421000302_ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78402-2"},{"key":"S1462399421000302_ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.046"},{"key":"S1462399421000302_ref98","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00599-3"},{"key":"S1462399421000302_ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8"},{"key":"S1462399421000302_ref95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"S1462399421000302_ref54","first-page":"147","article-title":"Management of corona virus disease-19 (COVID-19): the Zhejiang experience","volume":"49","author":"Xu","year":"2020","journal-title":"Zhejiang da Xue Xue Bao. Yi Xue Ban"},{"key":"S1462399421000302_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002"},{"key":"S1462399421000302_ref50","doi-asserted-by":"publisher","DOI":"10.3201\/eid2608.201160"},{"key":"S1462399421000302_ref11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2985"},{"key":"S1462399421000302_ref111","article-title":"CAR-NK cells effectively target the D614 and G614 SARS-CoV-2-infected cells","author":"Ma","year":"2021","journal-title":"bioRxiv."},{"key":"S1462399421000302_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2005.06.007"},{"key":"S1462399421000302_ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.02.001"},{"key":"S1462399421000302_ref41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027"},{"key":"S1462399421000302_ref68","first-page":"196","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Pdm","year":"2020","journal-title":"Clinical Trials"},{"key":"S1462399421000302_ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-10109-3"},{"key":"S1462399421000302_ref3","unstructured":"3. World Health Organization(WHO) Coronavirus Disease (COVID-19) Dashboard. Available at https:\/\/covid19.who.int\/ (Accessed on October 2021)."},{"key":"S1462399421000302_ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108234"},{"key":"S1462399421000302_ref120","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26102"},{"key":"S1462399421000302_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344"},{"key":"S1462399421000302_ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0421-x"},{"key":"S1462399421000302_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y"},{"key":"S1462399421000302_ref87","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1942227"},{"key":"S1462399421000302_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.001"},{"key":"S1462399421000302_ref44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4288"},{"key":"S1462399421000302_ref90","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00396-0"},{"key":"S1462399421000302_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102537"},{"key":"S1462399421000302_ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452"},{"key":"S1462399421000302_ref24","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1796425"},{"key":"S1462399421000302_ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.05.002"},{"key":"S1462399421000302_ref127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.10.005"},{"key":"S1462399421000302_ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606456"},{"key":"S1462399421000302_ref74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254453"},{"key":"S1462399421000302_ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102554"},{"key":"S1462399421000302_ref80","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6230"},{"key":"S1462399421000302_ref114","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0402-2"},{"key":"S1462399421000302_ref18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202003-0541OC"},{"key":"S1462399421000302_ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108837"},{"key":"S1462399421000302_ref61","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2019.1580513"},{"key":"S1462399421000302_ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007236"},{"key":"S1462399421000302_ref88","first-page":"doi: 10.1101\/2021.03.24.436620","article-title":"B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies","author":"Zhou","year":"2021","journal-title":"bioRxiv"},{"key":"S1462399421000302_ref47","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17034"},{"key":"S1462399421000302_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.02.001"},{"key":"S1462399421000302_ref59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008737"},{"key":"S1462399421000302_ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102898"},{"key":"S1462399421000302_ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106531"},{"key":"S1462399421000302_ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00858-2"},{"key":"S1462399421000302_ref104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"S1462399421000302_ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256141"},{"key":"S1462399421000302_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"S1462399421000302_ref46","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S330356"},{"key":"S1462399421000302_ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0732-3"},{"key":"S1462399421000302_ref110","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006619"},{"key":"S1462399421000302_ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbaexp.2006.08.003"},{"key":"S1462399421000302_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"S1462399421000302_ref71","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1890329"},{"key":"S1462399421000302_ref116","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02960-0"},{"key":"S1462399421000302_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"S1462399421000302_ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102598"},{"key":"S1462399421000302_ref64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00272-10"},{"key":"S1462399421000302_ref106","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01037-x"},{"key":"S1462399421000302_ref63","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59943"},{"key":"S1462399421000302_ref94","unstructured":"94. FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia https:\/\/www.cancernetwork.com\/view\/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia Accessed on September 2021."},{"key":"S1462399421000302_ref66","first-page":"e00299","article-title":"Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis","volume":"34","author":"Subbian","year":"2020","journal-title":"Clinical Microbiology Reviews"},{"key":"S1462399421000302_ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.12.002"},{"key":"S1462399421000302_ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00157"},{"key":"S1462399421000302_ref55","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5752"},{"key":"S1462399421000302_ref102","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0461-y"},{"key":"S1462399421000302_ref8","unstructured":"8. World Health Organization; COVID-19 clinical management: living guidance. Available at https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-1 (Accessed on September 2021)."},{"key":"S1462399421000302_ref30","unstructured":"30. World Health Organization. COVID-19 natural immunity: scientific brief, 10 May 2021. Available at https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci_Brief-Natural_immunity-2021.1 (Accessed on October 2021)."},{"key":"S1462399421000302_ref12","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1739565"},{"key":"S1462399421000302_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"S1462399421000302_ref93","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30600-7"},{"key":"S1462399421000302_ref27","doi-asserted-by":"publisher","DOI":"10.6026\/97320630016219"},{"key":"S1462399421000302_ref72","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022449613907"},{"key":"S1462399421000302_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30185-9"},{"key":"S1462399421000302_ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0820-9"},{"key":"S1462399421000302_ref5","first-page":"145","article-title":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China","volume":"41","year":"2020","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"S1462399421000302_ref84","doi-asserted-by":"publisher","DOI":"10.7326\/ACPJ202102160-015"},{"key":"S1462399421000302_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2020.06.013"},{"key":"S1462399421000302_ref82","article-title":"High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients","volume":"4","author":"Concepci\u00f3n","year":"2021","journal-title":"Life Science Alliance"},{"key":"S1462399421000302_ref123","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210187"},{"key":"S1462399421000302_ref108","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.297"},{"key":"S1462399421000302_ref91","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1957401"},{"key":"S1462399421000302_ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03662-x"},{"key":"S1462399421000302_ref35","first-page":"327","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"key":"S1462399421000302_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2020.03.001"},{"key":"S1462399421000302_ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00468-6"},{"key":"S1462399421000302_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4"}],"container-title":["Expert Reviews in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1462399421000302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T05:33:00Z","timestamp":1640669580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1462399421000302\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":127,"alternative-id":["S1462399421000302"],"URL":"https:\/\/doi.org\/10.1017\/erm.2021.30","relation":{},"ISSN":["1462-3994"],"issn-type":[{"type":"electronic","value":"1462-3994"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e24"}}